The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer

Clouth, B.; Chandrasekharan, Sankaran; Inwang, R.; Smith, Simon; Davidson, N.; Sauven, P.

doi:10.1016/j.ejso.2006.12.006

Cited by 32 publications

(25 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, pCR without any residual tumor in both breast and axillary lymph nodes after neoadjuvant chemotherapy is strong independent predictor of improved survival [24][25][26]. The studies in the literature showed that the rates of pCR have been much lower and have generally been less than 20% [27][28][29]. More recently, the use of taxanes in chemotherapy regimens has allowed a pCR rate of up to 34% [27,30], although a study indicated that the addition of taxanes to chemotherapy regimen obtained a marginal improvement to their pCR rate from 18% to 19.8% [28].…”

Section: Discussionmentioning

confidence: 97%

“…The studies in the literature showed that the rates of pCR have been much lower and have generally been less than 20% [27][28][29]. More recently, the use of taxanes in chemotherapy regimens has allowed a pCR rate of up to 34% [27,30], although a study indicated that the addition of taxanes to chemotherapy regimen obtained a marginal improvement to their pCR rate from 18% to 19.8% [28]. We found an increasing proportion of patients achieving a pCR from 11.5% in our previous study [20] to 13.5% in the presented study.…”

Section: Discussionmentioning

confidence: 98%

“…In our study also, there was a significant difference in the outcome between complete and partial pathological responders. On the other hand, some studies demonstrated that patients who had pCR in axillary lymph nodes but not in primary tumor of breast was an independent factor for outcome rather than pCR in breast only [21,24,28,31]. A study stated that pCR in axilla was associated with an excellent prognosis, even with a residual primary tumor, pointing to biologic differences between primary and metastatic cells [32].…”

Section: Journal Of Surgical Oncologymentioning

confidence: 94%

“…It was possible that these major strong factors had surpassed the effect of pCR on outcome. Pathological response to chemotherapy in the breast predicts nodal status, but a pCR in the breast does not necessarily imply a pCR in the axilla, as indicated above and therefore, they remain two important prognostic factors for outcome [28]. In the multivariate studies on breast carcinoma treated with neoadjuvant chemotherapy, the extent of nodal disease was consistently the most significant variable related to outcome [21,34,35], and after consideration of AS, pathological response to chemotherapy was not predictive of outcome [21].…”

Section: Journal Of Surgical Oncologymentioning

confidence: 95%

See 3 more Smart Citations

Triple negative phenotype and N‐ratio are important for prognosis in patients with stage IIIB non‐inflammatory breast carcinoma

Mersin

Yıldırım

Berberoğlu

et al. 2009

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 98%

Section: Journal Of Surgical Oncologymentioning

confidence: 94%

Section: Journal Of Surgical Oncologymentioning

confidence: 95%

See 2 more Smart Citations

Triple negative phenotype and N‐ratio are important for prognosis in patients with stage IIIB non‐inflammatory breast carcinoma

Mersin

Yıldırım

Berberoğlu

et al. 2009

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…21,22 Clouth et al have shown that the reduction in tumor enhancement on an MRI scan correlates with the extent of the disease as seen at the pathological examination. 23 But none of our patients underwent MRI for this assessment after NACT as the imaging technique is expensive in our perspective.…”

Section: Discussionmentioning

confidence: 99%

Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: A tertiary care center experience

et al. 2017

View full text Add to dashboard Cite

show abstract

Oncologic Breast Surgery

Mariotti¹

2014

Updates in Surgery

View full text Add to dashboard Cite

of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply , even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. It is our belief that oncologic breast surgery is a very complex specialty, which involves the surgeon in both phases of demolition and reconstruction. As the discipline is constantly evolving, surgeons often feel overwhelmed by the wealth of different data and the variety of information related to this specialty. Breast cancer is no more considered a disease of an organ, but rather affecting health at a systemic level. In addition, it is now possible to rely on advanced methods to determine the spread of cancer, and on more technically sophisticated surgical procedures for radical treatment.Hence the purpose, fully achieved by the Editors and the board of Authors invited, to provide the surgeon with an easy-to-read text, but nevertheless modern and complete, so as to override the contrast between the vanguard of scientific acquisitions and the practicality of surgery.The search for radical therapy associated with conservative surgery still represents the dilemma of those who get involved in the treatment of malignant breast tumors; the Authors seek answers to this question, highlighting, with admirable scientific rigor, how results are influenced by the consideration of the evaluation criteria of individual cases, and from these it is possible to deduce and apply increasingly radical curative strategies. Rome, September 2013Giorgio De Toma Foreword vSurgical treatment of malignant diseases of the breast represent...

show abstract

The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer

Cited by 32 publications

References 30 publications

Triple negative phenotype and N‐ratio are important for prognosis in patients with stage IIIB non‐inflammatory breast carcinoma

Triple negative phenotype and N‐ratio are important for prognosis in patients with stage IIIB non‐inflammatory breast carcinoma

Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: A tertiary care center experience

Oncologic Breast Surgery

Contact Info

Product

Resources

About